Article
The last day was jammed with important reports and research including the late breaking abstracts.
All News
Article
Curcumin, the active constituent of turmeric extract, has increasingly been promoted as a potential rheumatoid arthritis therapy, but data presented at ACR22 suggests that even in ideal situations, it is unable to do any better than placebo in replacing conventional RA therapies.
Article
A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized. Abstract 0402 is a retrospective study that looked at patients with psoriatic arthritis or ankylosing spondylitis in the FORWARD databank. It sheds new light and leaves us with some food for thought
Article
One of the enduring legacies of ACR 2022 for me will be the emphasis on polymyalgia rheumatica (PMR). Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run in this space. Read on for a quick PMR-roundup from the meeting!
Akhil Sood MD
Tweet
Abstr #2196- COVID-19 outcomes in IMID dx in large US Hospital
vs Pre-Omicron
- ↑ COVID + rate (21.9% vs 7.9%)
- ↓ hospitalized (0.8% vs 3%) & death (1.8% vs 4.5%)
- Hospitalization & death > gen pop both pd.
-Age & comorbidities assoc w worse outcomes
@RheumNow #ACR22
David Liew
Tweet
Biosimilar multi-switching in RA: is it an issue?
Switching back & forth between originator & biosimilar should create ideal conditions for immunogenicity or anti-drug Ab
This study: multi-switching vs no switching
No issues at all
Switch away in RA!
ABST1589 #ACR22 @RheumNow https://t.co/pGBF2BHp7y
Dr. John Cush
Tweet
We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/ygfYol5Z3f
Dr. John Cush
Tweet
ACR2022 Topic Panels https://t.co/5gMfFS8maR
David Liew
Tweet
@rheumecraig @RheumNow Absolutely. In this #ACR22 study, they did exclude anyone with deranged LFTs from this study and yet still two people in the turmeric arm got LFT derangement (vs zero in placebo). Sadly I don't think the turmeric salespeople are watching the LFTs.
Akhil Sood MD
Tweet
Abstr #2191 studies impact of maternal SLE on outcomes of children
Maternal SLE assoc w/ ↑ odds of
- SLE of children (HR 98.48, 95%CI:63.39-152.98)
- other AutoImm dx (HR 1.26, 1.02-1.57) (Hashimoto, JRA, IBD)
- Neurodev dx (1.35, 95%CI:1.15-1.57) (ADHD)
@RheumNow #ACR22
Dr. Rachel Tate
Tweet
UPA tx in prior TNFi tx PsA pts demonstrated consistent efficacy compared to the overall population in SELECT-PsA 2, regardless of number of prior anti-TNF therapies. Abs 2146 #ACR22 @RheumNow https://t.co/xnN4nvZ934 https://t.co/3S6ZzPvqVe
sheila
Tweet
How to adjust for GC correction when dose >/= 7.5mg/d using FRAX?
Calculate FRAX then
🦴For MOF risk multiply by 1.15
🦴HF risk multiply by 1.2
= adjusted risk (%)
(Adjustment of FRAX accdg to GC dose from Kanis et al., OI 2011)
#ACR22 @RheumNow @Rheumarhyme @PhRheumaJr https://t.co/qap1fFhF0h
Janet Pope
Tweet
What happens to #Sjogrens tests over time? Well nothing- serology and tests are stable over time for NIH in >2800 Pts from 1984-2020 in well characterized Pts. Abst#2025 #ACR22 @RheumNow I was surprised as I thought there would be worsening but if prevalent Pts already fibrotic?
Richard Conway
Tweet
Wheeler et al. MUC5B assoc risk RA-ILD, OR 2.25. No significant additive interaction with race, smoking, disease activity @RheumNow #ACR22 Abstr#2250 https://t.co/Hw2oBawKsd https://t.co/DqCQIPpEyg
Akhil Sood MD
Tweet
Abstr #2195 COVID PrEP in Rheum pts who did not seroconvert after 3rd dose
- anti-SARS-CoV2 IgG levels ↑ after day 1
- Saliva IgG also ↑ up to day 14
- one reported COVID+ w mild symptoms
@RheumNow #ACR22 https://t.co/um2JFNMhpj
Richard Conway
Tweet
Zuo @RayZuoMD @jasonsknight et al. High levels of anti-NET antibodies in 45% of aPL-positive patients May activate the complement cascade and contribute to brain white matter changes. @RheumNow #ACR22 Abstr#2269 https://t.co/JrjNvQRDim https://t.co/c4yXHLOmBJ
Janet Pope
Tweet
ILD in #scleroderma. #Scleroderma lung study III - NO DIFF between MMF + Pirfenidone vs MMF alone. Planned for 150 Pts but only 51 enrolled but p=0.9. A trial recruited during #COVID so difficult to enroll Abst#530 @RheumNow #ACR22 https://t.co/CBYEJ2YCVM
Catherine Sims, MD
Tweet
How does #COVID19 impact pregnant women with rheumatic disease? Does vaccination status make a difference? @RheumNow #ACR22
https://t.co/2oJ1RAeciN https://t.co/c9s6QRSOR4
Richard Conway
Tweet
Baker et al. Optum database study. Tofa assoc reduced incident RA-ILD. aHR 0.33 (vs ADA) @RheumNow #ACR22 Abstr#2251 #ACRbest https://t.co/R5rQ3KcHnq https://t.co/8Nq0t4zqQK
Janet Pope
Tweet
#Vasculitis #ACR22 highlights. #Rituximab more remission in clinical care for GPA - observational, less infections if 600 mg IV fixed q6 mo how long to continue? Abst#1084 and less flares w Rituximab maintenance in the MAINRITSAN studies abst#527 Ritux is new SoC in GPA @RheumNow
